Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
DALLAS--(BUSINESS WIRE)--EMA Phase 1b/2 Clinical Trial for LP-184.
Business Wire7/28/2026Neutral
LTRN
Lantern Pharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$33.17M
P/E Ratio
—
EPS
$-1.32
Beta
2.29
52W High
$5.74
52W Low
$1.11
50-Day MA
$3.48
200-Day MA
$3.13
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Lantern Pharma Inc
Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics, and machine learning. The company is headquartered in Dallas, Texas.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-16.59M |
| Operating Margin | 0.00% |
| Return on Equity | -157.40% |
| Return on Assets | -73.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.31 |
| Price-to-Book | 10.63 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $12.76M |
| Float | $9.45M |
| % Insiders | 20.32% |
| % Institutions | 14.22% |
Historical Volatility
HV 10-Day
54.50%
HV 20-Day
90.50%
HV 30-Day
86.17%
HV 60-Day
99.60%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($20.00 target)
2
BuyLatest News
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop targeted cancer therapies, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers." The allowed claims cover methods of selecting and treating patients with ovar.
Business Wire7/23/2026Neutral
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced the launch of ZetaOmics, the computational-biology module of its multi-agentic AI co-scientist platform, withZeta.ai. ZetaOmics introduces an autonomous “Computational Biologist” persona (agent) that performs real, end-to-end bioinformatics and multi-omic analysis — across any cancer type, and is purpose-built for the rare and pediatric cancers that have long been.
Business Wire7/8/2026Neutral
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
DALLAS--(BUSINESS WIRE)--Harmonic Presentation in form of 8K.
Business Wire6/2/2026Neutral
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received a successful response to its recent Type C meeting request from the U.S. Food and Drug Administration (FDA), focused on the ongoing Phase 2 HARMONIC™ trial of LP-300 in never-smokers with advanced non-small cell lung cancer (NSCLC) adenocarcinoma. In its written responses to Lantern's Type C meeting request, the FDA raised no objections to key.
Business Wire5/19/2026Neutral
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates.
Business Wire5/15/2026Neutral
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor.
Business Wire5/14/2026Neutral
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor.
Business Wire5/13/2026Neutral
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026.
Business Wire5/11/2026Neutral
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript
Seeking Alpha5/1/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LTRN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026